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Respiratory syncytial virus (RSV), a common respiratory pathogen in infants and the older population, causes
pulmonary inﬂammation and airway occlusion that leads to impairment of lung function. Here, we have
established a role for receptor for advanced glycation end products (RAGE) in RSV infection. RAGE-deﬁcient
(ager
2/2) mice were protected from RSV-induced weight loss and inﬂammation. This protection correlated
with an early increase in type I interferons, later decreases in proinﬂammatory cytokines, and a reduction in
viral load. To assess the contribution of soluble RAGE (sRAGE) to RSV-induced disease, wild-type and ager
2/2
mice were given doses of sRAGE following RSV infection. Of interest, sRAGE treatment prevented RSV-induced
weight loss and neutrophilic inﬂammation to a degree similar to that observed in ager
2/2 mice. Our work
further elucidates the roles of RAGE in the pathogenesis of respiratory infections and highlights the opposing
roles of membrane and sRAGE in modulating the host response to RSV infection.
Respiratory syncytial virus (RSV)–induced disease is
characterized by inﬂammation, epithelial cell necrosis,
and mucus overproduction that occludes the small air-
ways of infants, leading to hypoxia and wheezing in
acute disease, and in some cases, wheezing throughout
childhood [1, 2]. In addition to being detrimental to
very young individuals, RSV also poses a signiﬁcant
threat to the older population [3]. Recently, a new
at-risk population for RSV infection was identiﬁed:
patients with chronic obstructive pulmonary disease
(COPD). The incidence of COPD is increasing, and it is
predicted to be the third leading cause of death world-
wide by 2030 [4]. RSV has been identiﬁed as a compo-
nent of both stable and acute exacerbations of COPD
(AECOPD) [5–11]. Moreover, the persistence of RSV in
stable COPD has been associated with inﬂammation and
a decrease in the forced expiratory volume in 1 second
(FEV1) [11]. These data suggest that a treatment that
is effective at limiting RSV pathogenesis may be a valid
approach to limiting RSV-induced disease and AECOPD.
Receptorforadvancedglycationendproducts(RAGE)
can exist as a transmembrane or soluble protein [12]
and binds to a variety of ligands that are released
during cellular damage or stress, including advanced
glycation end products, High Mobility Group Box
Chromosomal Protein 1 (HMGB-1), DNA, several
S100 family members, and b-amyloid [13]. RAGE is
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thelial cells in healthy lung tissue from humans and mice, re-
spectively [14, 15]. Expression has also been reported on
vascular endothelial cells, neutrophils, macrophages, and den-
dritic cells. In studies using ager
2/2 mice, RAGE has been shown
to play detrimental roles in response to both inﬂuenza A [16]a n d
Streptococcus pneumonia [17], two known mediators of AECOPD.
In this study, we examined the role of RAGE in RSV infection
with the hypothesis that RAGE may contribute to the ability of
RSV to cause AECOPD.
Here, we demonstrate that endogenous RAGE serves to ex-
acerbate RSV-induced disease. Speciﬁcally, ager
2/2mice were
markedly protected from RSV-induced weight loss and lung
inﬂammation. This phenotype was accompanied by small but
signiﬁcant decreases in viral RNA and proteins, compared with
wild-type (WT) controls. The protective effects of RAGE de-
ﬁciency were associated with an early increase in the type I
interferons(IFN-I)andadecreaseinproinﬂammatorycytokines
at 5 days after infection. Levels of soluble RAGE (sRAGE) were
elevated in the bronchoalveolar lavage ﬂuid (BALF) of WT
mice at 5 days after infection, a time point that coincided with
weight loss and inﬂammation; however, our data suggest that
sRAGE is anti-inﬂammatory and serves to self-limit the
inﬂammatory response. Our ﬁndings highlight the opposing
functions of membrane and sRAGE and suggest that modu-
lation of RAGE, either by complete removal of the protein,
or by administration of sRAGE, has the potential to dampen




ager (Gene product, RAGE) knockout mice were generated by
Taconic Artemis Pharmaceuticals by means of the targeting
strategy detailed in Figure 1. C57/B6 and ager
2/2 mice were
housed under speciﬁc pathogen-free conditions at Taconic Farms
and MedImmune. All experiments were approved by Med-
Immune’s internal Institutional Animal Use and Care Committee.
RSV Propagation
RSV A2 strain virus was propagated in Hep2 cells. Cells were
infected with virus at a multiplicity of infection of 0.1 plaque-
forming units/cell. At 4–5 days after infection, viable virion
particles were harvested from infected cultures by performing
multiple freeze-thaw cycles on the infected cell pellet. Sus-
pension was clariﬁed by centrifugation, and supernatant con-
taining infectious virions was stored at 280C.
RSV Infection and Necropsy
Mice were anesthetized with isoﬂuorane before intranasal in-
oculation with 50 lL of RSV (6.78 3 10
6 plaque-forming units)
or media. Miceweremonitoreddailyfor weightloss. Atthe time
of necropsy, we collected blood, BALF, and lung tissue samples
(for RNA, protein, lung dispersions, and histological exam-
ination). An in-house preparation of sRAGE-huFc or human
immunoglobulin (Ig) G Fc fragment (Jackson Immunoresearch)
was administered intranasally in 50-lgd o s e s .
Determination of Viral Load
A plaque assay, genome-transcript analysis, and enzyme-linked
immunosorbent assay (ELISA) were used to determine viral
load in RSV-infected WT and ager
2/2 mice. Serial dilutions
of lung or nasal turbinate homogenates were used to determine
lungviraltiterswithuseofplaqueassaybytitrationonconﬂuent
Hep-2 or Vero cells. On day 5–7 after infection, cell monolayers
were ﬁxed and were immunostained with anti-RSV antibodies
to identify plaques [18]. We used real-time polymerase chain
reaction primer-probe sets for RSV N, RSV SH-G, and RSV
NS1 to assess viral genome and transcript, viral genome, and
viral transcript, respectively. Analysis of RSV proteins in lung
tissue and BALF samples was done using an RSV ELISA, as
described elsewhere [19].
RNA Isolation and Gene Expression Analyses
Lung tissue for RNA analysis was incubated in RNAlater
(Ambion) and was maintained at 4C overnight, after which the
RNAlater was removed and the tissues were frozen at 280C.
RNA was isolated from homogenized tissue using the RNeasy
kit from Qiagen. RNA was reverse-transcribed using the Super-
script III RT system (Invitrogen). Relative cytokine-chemokine
transcript expression was assessed using the Fluidigm Biomark
Dynamic array loaded with probes for transcripts of interest.
Quantification of Cytokine and Chemokine Levels
Lung tissue was homogenized in the presence of Complete
protease inhibitors (Roche), and cytokines were measured
using an MSD platform (MesoScale Diagnostics). RAGE levels
were assessed using a duoset purchased from R&D Systems.
Myeloperoxidase (MPO) was assessed using a kit from Cell
Sciences. IFN-I levels were assessed using kits from PBL In-
terferon Source.
Lung Dispersions and Flow Cytometry Fluorescence Activated
Cell Sorting
Lung tissue was processed into a single cell suspension after
incubation with a solution of 0.22 Wunsch U/mL of Liberase
and 0.01 U/lL DNAse in RPMI (Roche). Antibodies used for
staining included those against CD4, CD8, TCRb,D X 5 ,C D 1 9 ,
F4/80, Gr1, CD11c, B220, and PDCA1. All antibodies were
purchased from BD Biosciences.
Histological Analyses
Lung tissue harvested for histological analyses was inﬂated
with 10% buffered formalin before parafﬁn embedding and
sectioning. Tissue sections were stained with hematoxylin-eosin.
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RAGE Expression in Small Airways of WT Mice
RAGE-deﬁcient (ager
2/2) mice were generated using a vector
that targeted exons 2–7 of ager for deletion (Figure 1A).
Lungs from C57/BL6 WT and ager
2/2 mice were
immunohistochemically stained for RAGE to identify the
RAGE-expressing cells. RAGE, as indicated by red staining,
was highly expressed in types I and II alveolar epithelial cells
lining the small airways but not in the large airways, inter-
stitium, or endothelium (Figure 1B). Of importance, no
immunoreactivity for RAGE was detected in ager
2/2 mice
Figure 1. A, Receptor for advanced glycation end products (RAGE) protein is absent in ager
2/2 mice, generated using a targeting construct to
delete exons 2–7. B, C, Small airways of wild-type (WT) mice (B)b u tn o tager
2/2 mice (C) express RAGE protein, as indicated by red staining.
D, Immunohistochemical results were confirmed by enzyme-linked immunosorbent assay analysis.
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basal levels of RAGE in the lung tissue (Figure 1D)a n d
BALF (Figure 1D) from WT mice, whereas RAGE levels in
ager
2/2 mice were undetectable or at background levels
(Figure 1D).
Protection From RSV-Induced Weight Loss in ager
2/2 Mice
RSV infection causes transient weight loss in mice [20–25],
and this parameter is often used to assess virus-induced illness
[26,27].Inourmodel,bothRSV-infectedWTandager
2/2 mice
exhibited a transient weight loss of similar magnitude at 1 day
after infection. Mice recovered from this weight loss before
beginning a second period of weight loss starting at 4 days af-
ter infection, relative to sham controls (Figure 2). Peak weight
loss in RSV-infected WT mice (80% 6 2% of original body
weight) was observed at 6 days after infection. However, this
value reﬂects only the weight loss for mice that were moni-
tored over the full period; 13 of the 22 RSV-infected WT mice
were euthanized at 7 days after infection because of $25% loss
of their original body weight (according to MedImmune
Institutional Animal Care and Use Committee guidelines). In
comparison, thedegreeof RSV-inducedweightlossinager
2/2
mice (90% 6 1% at 6 days after infection) was signiﬁcantly
reduced relative to WT controls. None of the ager
2/2 mice
lost $25% of their original body weight.
Reduced Viral Load in Nasal Turbinates of ager
2/2 Mice
We next examined the viral load 4 days after infection, when
peak viral titers were recovered from RSV-infected WT mice
[28]. Viral titers from WT and ager
2/2 mice were similar, with
Figure 2. ager
2/2 mice are protected from respiratory syncytial virus
(RSV)–induced weight loss. Wild-type (WT) and ager
2/2 mice
were infected with RSV or media (sham), and weight loss was monitored
over a period of 14 days. Graph represents pooled weight change
data 6 standard error of the mean from 2 experiments (n 5 6–22).
Statistically significant difference between RSV-infected WTand ager
2/2
mice: *P #.05, **P #.01, ***P #.001.
Figure 3. ager
2/2 mice have a reduced viral load after respiratory syncytial virus (RSV) infection. A, B, ager
2/2 mice had significantly fewer plaque-
forming units (PFUs) per gram isolated from nasal turbinates (A) but not lung tissue (B), compared with wild-type (WT) mice. C, ager
2/2 mice displayed
statistically significant decreases in viral genome and/or transcript RNAs. Primers for N protein, SH-G, and NS1 were designed to amplify genome and
transcripts, genome only, and transcripts only, respectively. Data are plotted as fold change in RNA relative to RSV-infected WT mice. D, ager
2/2 mice
had lower levels of viral antigens than did WT mice, as determined by enzyme-linked immunosorbent assay. All data are plotted as mean 6 standard
error of the mean and are representative of $2 separate experiments. *P #.05, **P #.01, ***P #.001.
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nasal turbinates of ager
2/2 mice (Figure 3A and 3B). In addi-
tion, we observed a signiﬁcant decrease in RSV RNA in ager
2/2
mice with use of primers for RSV N, SH-G, and NS1, which
detected genome and transcript, genome only, and transcript
only, respectively. The ager
2/2 mice had a mean of 7-fold less
N protein, 5.5-fold less SH-G, and 74-fold less NS1, compared
with WT mice (Figure 3C). Correspondingly, levels of RSV
antigens in the lung were reduced signiﬁcantly in the absence
of RAGE (Figure 3D).
Dampened RSV-Induced Inflammation in the Absence of RAGE
At 5 days after infection, the total cell numbers in BALF and
lung tissue were markedly reduced (50%) in RSV-infected
ager
2/2 mice, compared with WT controls (Figure 4A and 4C).
Differential counts revealed that the reduction in total BALF
inﬂammation was attributable to fewer inﬁltrating macrophages
and neutrophils (Figure 4B). Accordingly, histological analyses
showed that perivascular and peribronchial inﬂammation was
reduced in the lungs of the ager
2/2 mice (Figure 4D). Although
RSV infection in WT mice resulted in the recruitment of
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infection. Infection of mice with ultraviolet-inactivated RSV
did not induce pulmonary inﬂammation (Figure 4A and 4C).
Figure 4. Respiratory syncytial virus (RSV)–induced inflammation is dampened in the absence of receptor for advanced glycation end products (RAGE).
A, B, RSV-infected ager
2/2 mice have less inflammation in bronchoalveolar lavage fluid (BALF) at 120 hours after infection, relative to RSV-infected
wild-type (WT) controls (A); specifically, there were fewer macrophages and neutrophils (B), as assessed by differential counts. C, D, RSV-infected ager
2/2
mice had decreased lung tissue inflammation, compared with RSV-infected WT mice, as assessed by lung digests (C) and histology (D). Arrowheads
indicate airway and perivascular inflammation, both reduced in ager
2/2 mice at 120 hours after infection (D). Data in panels A–C are plotted as the
mean 6 standard error of the mean and are representative of $ 2 separate experiments. E, Flow cytometric analysis of lung digests from RSV-infected
ager
2/2 and WT mice show that the former have decreases in many leukocyte populations relative to the latter. Plotted FACS data represent pooled data
from 3 separate experiments, with 3–6 animals per experiment. *P # .05, **P # .01 (difference between RSV-infected WT and ager
2/2 mice at
a particular time point).
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ager
2/2 Mice
To further elucidate the mechanism by which RAGE was reg-
ulating RSV-induced inﬂammation, we assessed cytokine and
chemokine production in WT and ager
2/2 mice. Of interest, we
observed that ager
2/2 mice mounted an early IFN-I response
after RSV infection that was 2–3-times greater than that observed
in WT mice (Figure 5A). However, at 5 days after infection,
many of the mediators that were elevated in RSV-infected
WT mice were signiﬁcantly reduced in ager
2/2 mice, including
monocyte chemoattractant protein 1 (MCP-1, CC chemokine
motif ligand 2, CCL2), keratinocyte chemoattractant (KC),
interleukin-10, IFN-c, and tumor necrosis factor a (TNF-a)
(Figure 5B).
Up-regulation of sRAGE Caused by RSV Infection
We next asked whether RSV infection had an effect on the
expression of RAGE and RAGE ligands. Levels of sRAGE
were signiﬁcantly increased in BALF from WT mice after
RSV infection and, of the time points tested, were highest at
5 days after infection (Figure 6). In contrast to published data
from other infection models [16, 17], we did not observe RSV-
induced increases in RAGE with use of real-time polymerase
chain reaction or immunohistochemistry (data not shown).
Furthermore, up-regulation of the RAGE ligands S100A8/A9
and HMGB-1 was variable and was not observed in all of the
experiments conducted.
sRAGE Is Protective During RSV Infection
To determine the role of sRAGE in RSV infection, we in-
tranasally administered sRAGE or IgG-Fc to mice at 8 hours
and 3 days after infection. Administration of exogenous sRAGE
elevated levels of sRAGE in the BALF of RSV-infected WT
mice to 2–3-times the levels observed with RSV infection
alone (Figure 7A). It was surprising that reconstitution of
ager
2/2 mice with sRAGE did not dramatically alter the course
Figure 5. Respiratory syncytial virus (RSV)–infected ager
2/2 mice have altered cytokine and chemokine profiles. RSV-infected ager
2/2 mice display
enhanced levels of IFN-I at 24 hours after infection (A) and decreased RNA (gray bars) and protein (black bars) levels for many cytokines and chemokines
at 120 hours after infection (B), relative to RSV-infected wild-type (WT) controls. Fold changes in RNA were calculated relative to sham-infected
WTanimals. All data are plotted as mean 6 standard error of the mean. Protein data are representative of $2 separate experiments with 4–8 animals
per group. RNA data were generated by pooling samples from a variety of experiments with a total sample number of 12 per experimental group.
*P #.05, **P #.01, ***P #.001 (difference between RSV-infected WT and ager
2/2 mice at a particular time point).
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RSV-infected WT mice with sRAGE conferred protection from
RSV-induced weight loss to a degree similar to RAGE deﬁciency
(Figure 7B). Furthermore, sRAGE administration markedly re-
duced total cell counts in BALF from WT mice (Figure 7D)a n d
neutrophilic airway inﬂammation in RSV-infected WT mice
and ager
2/2 mice, as assessed by differential cell counts and
levels of myeloperoxidase in the BALF (Figure 7E and 7F).
sRAGE alone or in the context of RSV infection did not alter
levels of proinﬂammatory cytokines, including IFN-I and tumor
necrosis factor a, in BALF or lung tissue (data not shown).
DISCUSSION
Viral and bacterial infections in the airways of infants or in the
context of a lung with COPD can result in an ampliﬁcation
of the host response that leads to severe lung damage, airﬂow
obstruction, and increased mortality. RAGE is highly expressed
in the lungs, and there is recent literature suggesting that
RAGE deﬁciency is protective in mouse models of infection,
including cecal ligation puncture sepsis [29, 30], pulmonary
inﬂuenza A [16], and Streptococcus pneumoniae infection [17].
In the latter 2 models, which used pathogens associated with
AECOPD, a RAGE deﬁciency enhanced survival without com-
promising pathogen clearance. In fact, the absence of RAGE
led to increased killing of S. pneumoniae [17] and to increased
clearance of inﬂuenza A [16].
Although the aforementioned studies revealed a clear role
for RAGE in mediating mortality after infection, the effect of
RAGE on pathogen-induced inﬂammation was not carefully
addressed. Thus, we chose to examine the role of RAGE in the
context of RSV-induced inﬂammation. We report here that the
absence of RAGE markedly protected against RSV-induced
illness and airway and lung inﬂammation. Our results support
the previous ﬁndings that RSV-induced weight loss is related
to magnitude of the CD8
1 T-cell response [26, 31]. However,
although total CD8
1 T-cell counts were decreased in lungs
from RSV-infected ager
2/2 mice, antigen-speciﬁc CD8
1 T cell
counts were not (data not shown). It should be noted that
a role for endothelial RAGE in mediating vascular leukocyte
adhesion has been established [17, 29, 32, 33]; however, we
were unable to demonstrate an underlying defect in leukocyte
recruitment to the lungs in ager
2/2 mice. First, we did not
observe RAGE expression on murine lung endothelium either
before (Figure 1A) or after RSV infection (data not shown).
Second, KC- or macrophage inﬂammatory protein-1a–
induced pulmonary inﬂammation was similar in WT and
ager
2/2 mice (data not shown), showing that chemokine-
mediated leukocyte recruitment was intact in ager
2/2 mice.
At 8 and 24 hours after infection, RSV-infected ager
2/2 mice
had signiﬁcantly elevated levels of IFN-I, namely, IFN-a and
IFN-b, compared with RSV-infected WT mice. Although
plasmacytoid dendritic cells are thought to be the major
producers of IFN-I after viral infection, airway epithelial cells
are the primary source of IFN-I during RSV infection in vivo
[34]. IFN-I are widely recognized as antiviral cytokines that
help prevent viral spread; however, their role during RSV
infection is unclear. In vitro, it has been shown that RSV in-
terferes with the IFN-I signaling pathway [35], suggesting that
these cytokines are an important component of the innate
immune response to RSV. However, only low levels of IFN-I
have been observed in infected infants, and these levels did not
correlate with viral shedding and/or recovery [36]. Although
treatment of mice with IFN-a before RSV infection resulted in
a small decrease in viral titers [37], IFN-a2a treatment of RSV-
infected children did not alter the clinical scores from children
treated with the vehicle [38]. Together, these data suggest
a limited role for IFN-I in the context of RSV-induced dis-
ease, thus making it unlikely that the exaggerated IFN-I re-
sponse in ager
2/2 mice is responsible for their protection from
disease.
We observed elevated levels of sRAGE in BALF from RSV-
infected WT mice at 5 days after infection. Unlike in reports
from other models, we did not see an up-regulation of mem-
brane RAGE or HMGB-1 in our infection model [16, 17]. There
are conﬂicting views regarding the role of sRAGE in in-
ﬂammation.Althoughsomestudies haveshownthat sRAGEcan
induce proinﬂammatory cytokine secretion and can mediate
macrophage and neutrophil migration, survival, and differen-
tiation [39, 40], others have implicated an anti-inﬂammatory
role for sRAGE. Speciﬁcally, sRAGE has been shown to block
leukocyte recruitment in models of diabetic inﬂammation [41,
42], peritonitis [33], sepsis [29], arthritis [39], and lipopoly-
saccharide-induced lung inﬂammation [43]. These studies argue
that sRAGE acts as a decoy receptor to sequester its ligands from
Figure 6. Soluble receptor for advanced glycation end products
(sRAGE) is up-regulated during respiratory syncytial virus (RSV) infection.
Levels of sRAGE in the bronchoalveolar lavage fluid (BALF) were
significantly increased at 120 hours after infection with RSV.
Representative data are shown, with 5–8 mice per group. *P # .05
(significant increase in sRAGE compared with sham-infected animals).
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response. A more recent study by Koch et al [44]s u g g e s t st h a t
sRAGE antagonizes the function of membrane RAGE by
physically interacting with membrane RAGE via homotypic
interactions and thus preventing the clustering and subsequent
signaling through this receptor.
Increases in sRAGE correlate with inﬂammation and dis-
ease in diabetes [45, 46], sepsis [47], and in our model of RSV
infection, which lead us to hypothesize that sRAGE was or-
chestrating the inﬂammatory response. Therefore, we anti-
cipated that reconstitution of ager
2/2 mice with sRAGE
would phenocopy the disease observed in RSV-infected WT
mice. However, addition of sRAGE did not exacerbate RSV
disease in ager
2/2 mice but, instead, diminished the severity
of disease in RSV-infected WT mice. It seems counterintuitive
that both RAGE deﬁciency and treatment of WT mice with
exogenous RAGE could be beneﬁcial during RSV infection.
Instead, we conclude that there are opposing functions of
membrane RAGE and sRAGE. Under normal conditions,
RAGE binds its ligands and induces inﬂammation. However, in
the presence of sRAGE, the proinﬂammatory signaling cascade
downstream of membrane RAGE is dampened either by
Figure 7. Soluble receptor for advanced glycation end products (sRAGE) protects from parameters of respiratory syncytial virus (RSV)–induced disease.
Wild-type (WT) and ager
2/2 mice were sham or RSV infected and administered intranasally with 50 lg of sRAGE or immunoglobulin (Ig) G–Fc at 8 hours
and 3 days after infection. A, sRAGE-treated RSV-infected mice displayed levels of RAGE that were significantly increased above RAGE levels with
RSV infection only. B–F, sRAGE protected WT mice (B) but not ager
2/2 mice (C) from RSV-induced weight loss and bronchoalveolar lavage fluid (BALF)
inflammation (D), specifically in neutrophils as evidenced by differential counts (E) and myeloperoxidase levels (F). Data are plotted as mean 6 standard
error of the mean and represent 2 pooled experiments with 10–16 animals per group. *P #.05, **P #.01, ***P #.001.
1318 d JID 2012:205 (15 April) d Miller et alligand sequestration or by physical disruption of the signaling
complex [44]. Under these circumstances, proinﬂammatory
RAGE signaling would not occur in ager
2/2 mice and would be
attenuated with sRAGE treatment of WT mice.
The exact means by which RAGE signaling impacts the path-
ogenesis of RSV-induced disease are not yet clear. However,
our data provide some insights into potential mechanisms.
First, RAGE seems to be a negative regulator of IFN-I, and the
enhanced IFN-I production observed in ager
2/2 mice may
help to limit viral spread. Second, our data implicate RAGE
in RSV-induced inﬂammation, because the absence of RAGE
signiﬁcantly reduced RSV-induced leukocyte recruitment to
the lungs. Finally, these data highlight the differences in the
functions of membrane and sRAGE. Although signaling via
membrane RAGE induces an inﬂammatory response, inter-
actions between soluble and membrane RAGE and ligand
binding to sRAGE seem to be mechanisms by which the host
can down-modulate inﬂammation.
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